Sichuan Huiyu Pharmaceutical Co., Ltd. () Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Sichuan Huiyu Pharmaceutical Co., Ltd.

Why is Sichuan Huiyu Pharmaceutical Co., Ltd. ?

Poor long term growth as Net Sales has grown by an annual rate of -15.85% and Operating profit at -139.44% over the last 5 years

Negative results in Sep 25

NET SALES(HY) At CNY 502.7 MM has Grown at -17.49%
NET PROFIT(HY) At CNY 53.87 MM has Grown at -31.32%
ROCE(HY) Lowest at 1.24%

Underperformed the market in the last 1 year

The stock has generated a return of 6.63% in the last 1 year, much lower than market (China Shanghai Composite) returns of 22.49%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Sichuan Huiyu Pharmaceutical Co., Ltd. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Sichuan Huiyu Pharmaceutical Co., Ltd.

-29.71%

0.64

57.50%

China Shanghai Composite

3.56%

1.58

14.20%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-13.81%

EBIT Growth (5y)

-48.85%

EBIT to Interest (avg)

84.17

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.59

Sales to Capital Employed (avg)

0.23

Tax Ratio

100.00%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

12.11%

ROE (avg)

5.57%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.63

EV to EBIT

150.52

EV to EBITDA

42.91

EV to Capital Employed

2.38

EV to Sales

4.01

PEG Ratio

1.92

Dividend Yield

ROCE (Latest)

1.58%

ROE (Latest)

3.45%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Mildly Bearish

Dow Theory

Mildly Bullish

No Trend

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

14What is working for the Company

OPERATING CASH FLOW(Y)

Highest at CNY 255.8 MM

NET SALES(HY)

At CNY 551.86 MM has Grown at 21.79%

RAW MATERIAL COST(Y)

Fallen by -0.16% (YoY

NET PROFIT(9M)

Higher at CNY 119.92 MM

EPS(Q)

Highest at CNY 0.06

-8What is not working for the Company

INTEREST(HY)

At CNY 6.17 MM has Grown at 17.07%

INVENTORY TURNOVER RATIO(HY)

Lowest at 1.15 times

DEBTORS TURNOVER RATIO(HY)

Lowest at 5.57 times

Here's what is working for Sichuan Huiyu Pharmaceutical Co., Ltd.

Net Profit

At CNY 119.92 MM has Grown at 168.03%

Year on Year (YoY)

MOJO Watch

Net Profit trend is very positive

Net Profit (CNY MM)

Operating Cash Flow

Highest at CNY 255.8 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (CNY MM)

Net Sales

At CNY 551.86 MM has Grown at 21.79%

Year on Year (YoY)

MOJO Watch

Near term sales trend is positive

Net Sales (CNY MM)

EPS

Highest at CNY 0.06

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (CNY)

Net Profit

Higher at CNY 119.92 MM

than preceding 12 month period ended Jun 2026

MOJO Watch

In the nine month period the company has already crossed sales of the previous twelve months

Net Profit (CNY MM)

Raw Material Cost

Fallen by -0.16% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Sichuan Huiyu Pharmaceutical Co., Ltd.

Interest

At CNY 6.17 MM has Grown at 17.07%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Inventory Turnover Ratio

Lowest at 1.15 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Debtors Turnover Ratio

Lowest at 5.57 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio